Literature DB >> 10694816

Drug selection of MDR1-transduced hematopoietic cells ex vivo increases transgene expression and chemoresistance in reconstituted bone marrow in mice.

T Licht1, S K Goldenberg, W D Vieira, M M Gottesman, I Pastan.   

Abstract

The MDR1 (multidrug resistance) gene, transferred to hematopoietic cells, is expected to protect them from anticancer chemotherapy and may serve as a selectable marker, restoring gene expression in vivo. Appropriate selection strategies, however, need to be established. To investigate whether preselection ex vivo affects chemoresistance, murine bone marrow cells were retrovirally transduced with high-titer or, as a model for suboptimal gene expression, low-titer retroviruses and exposed to daunomycin or colchicine for 48-96 h. Selection significantly increased chemoresistance of clonogenic progenitor cells. In tissue culture, the entire target population was rendered highly drug resistant after MDR1 transfer with high-titer viruses. If transduction was performed under suboptimal conditions, drug selection increased the frequency of chemoresistant colonies up to 40% over the number of unselected cells. Colchicine and daunomycin were equally efficient in increasing drug resistance ex vivo, but colchicine-preselected cells rescued lethally irradiated mice under conditions where daunomycin-selected bone marrow cells failed to do so. Hence, while hematopoietic cells can be protected by MDR1, the selection strategy is critical for repopulation of bone marrow with transduced cells. Preselection in culture before transplantation significantly increased P-gp expression and chemoresistance in vivo in mice reconstituted with transduced bone marrow cells. This study may help to facilitate the use of MDR1 as a selectable marker in gene therapy of the hematopoietic system. Gene Therapy (2000) 7, 348-358.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10694816     DOI: 10.1038/sj.gt.3301087

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  4 in total

1.  Protection of CHO cells by transfer of survivin driven by ovarian-specific promoter OSP-2.

Authors:  Chun-Hua Tu; Wei-Peng Liu; Mei Dong; Li-Ping Cai; Ya-Qin Mo; Dong-Zi Yang
Journal:  Mol Biol Rep       Date:  2010-11-14       Impact factor: 2.316

2.  The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines.

Authors:  Taryn E Dick; Jeremy A Hengst; Todd E Fox; Ashley L Colledge; Vijay P Kale; Shen-Shu Sung; Arun Sharma; Shantu Amin; Thomas P Loughran; Mark Kester; Hong-Gang Wang; Jong K Yun
Journal:  J Pharmacol Exp Ther       Date:  2015-01-06       Impact factor: 4.030

3.  Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrow.

Authors:  Thomas Licht; Mark Haskins; Paula Henthorn; Sandra E Kleiman; David M Bodine; Todd Whitwam; Jennifer M Puck; Michael M Gottesman; John R Melniczek
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

4.  Chemoprotection of murine hematopoietic cells by combined gene transfer of cytidine deaminase (CDD) and multidrug resistance 1 gene (MDR1).

Authors:  Sebastian Brennig; Nico Lachmann; Theresa Buchegger; Miriam Hetzel; Axel Schambach; Thomas Moritz
Journal:  J Exp Clin Cancer Res       Date:  2015-12-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.